ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1129

Discordance in Patient and Physician Assessment of Disease Activity in Relapsing Polychondritis

Emily Rose1, Marcela Ferrada1, Kaitlin Quinn2, Wendy Goodspeed1, Laurent Arnaud3 and Peter C. Grayson4, 1Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, 3Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, 4Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

Meeting: ACR Convergence 2020

Keywords: cartilage, Disease Activity, Measurement Instrument, Outcome measures, Response Criteria

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Relapsing polychondritis (RP) is a rare chronic disabling inflammatory condition primarily affecting cartilage tissue. Self-reported patient outcome measures, which have not been evaluated in RP, are necessary to understand how RP disease manifestations affects patients. The objective of this study was to compare patient and physician assessment of disease activity in a cohort of patients with RP to determine the need for multimodal response criteria in RP.

Methods: Adult patients who fulfilled diagnostic criteria for RP were recruited into a prospective, observational cohort. Patients underwent a standardized comprehensive evaluation at six-month interval visits that included a clinical evaluation by rheumatology and otolaryngology, laboratory studies, audiology, and chest imaging. From this information, physicians rated the Physician Global Assessment (PhGA) on a scale of 0 to 10. Patients simultaneously completed four patient-reported outcome questionnaires: Patient Global Assessment (PtGA), SF-36 Health Survey, Brief Illness Perception Questionnaire (BIPQ), and Multidimensional Fatigue Inventory (MFI). The intraclass correlation coefficient (ICC) (2, 1) was calculated to determine the agreement between physicians and patients. Patient – Physician discordance was defined as a difference (PtGA-PhGA). Visit characteristics were compared between the positive discordant group and the concordant group using Mann Whitney or Fisher’s exact test.  Response to treatment was analyzed in all patients who had at least two study visits. 

Results: A total of 154 visits from 76 patients were analyzed. The median PhGA was 3 (interquartile range 2-3) and median PtGA was 5 (interquartile range 4-7). The ICC was low (0.14; 95% confidence interval -0.06 to 0.334, p=0.10). PtGA and PhGA were concordant in 66 visits (42.6%). In a total of 84 visits (54.2%), patients scored disease activity 3 or more points higher than physicians (positive discordance), whereas in only 4 visits (2.6%) PtGA was 3 or more points less than PhGA (negative discordance). Compared to visits with concordance, visits with positive discordance were associated significantly with worse scores on the MFI, BIPQ, SF 36 Physical component score (PCS), and SF 25 Mental component score (MCS). There were no differences in demographics, medication use, clinical symptoms, or objective measures of airway inflammation between the concordant and positively discordant groups. Treatment was increased over 52 visit intervals in 36 patients. Whereas PhGA scores significantly improved in response to increased treatment from a median 3 (interquartile range 2-4) to 2 (interquartile range 2-3) (P< 0.01), there was no significant change in PtGA.  (Figure 1)

Conclusion: Patients with RP typically self-report higher disease activity than their physician counterparts and do not necessarily perceive similar improvement in response to treatment.  Discordance is possibly due to the psychological burden of illness experienced by patients. Future disease activity assessment instruments in RP should consider the utilization of composite response criteria that incorporate patient-reported outcome measures.

Figure 1. Increased treatment improves disease activity from physician (median change PhGA=-1 , IQR= -2-0) but not patient perspective (median change PtGA=0 , IQR= -1-1)


Disclosure: E. Rose, None; M. Ferrada, None; K. Quinn, None; W. Goodspeed, None; L. Arnaud, Alexion, 8, Amgen, 8, Astra-Zeneca, 8, GSK, 8, Janssen-Cilag, 8, LFB, 8, Lilly, 8, Menarini France, 8, Novartis, 8, Pfizer, 8, Roche-Chugaï, 8, UCB, 8; P. Grayson, None.

To cite this abstract in AMA style:

Rose E, Ferrada M, Quinn K, Goodspeed W, Arnaud L, Grayson P. Discordance in Patient and Physician Assessment of Disease Activity in Relapsing Polychondritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/discordance-in-patient-and-physician-assessment-of-disease-activity-in-relapsing-polychondritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discordance-in-patient-and-physician-assessment-of-disease-activity-in-relapsing-polychondritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology